Theravance Biopharma, Inc. (TBPH)
| Market Cap | 494.86M |
| Revenue (ttm) | 51.27M |
| Net Income (ttm) | 868.54M |
| Shares Out | 52.81M |
| EPS (ttm) | 11.70 |
| PE Ratio | 0.80 |
| Forward PE | 7.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 592,854 |
| Open | 9.10 |
| Previous Close | 9.11 |
| Day's Range | 9.01 - 9.40 |
| 52-Week Range | 8.76 - 12.03 |
| Beta | 0.43 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+81.43%) |
| Earnings Date | Nov 6, 2023 |
About TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for TBPH stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 81.43% from the latest price.
News
Theravance Biopharma to Participate in an Upcoming Investor Conference
DUBLIN , Aug. 29, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, Septemb...
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders
DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension ...
Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 2022 1 Q2 2023 YUPELRI total retail TRx and new to product TRx again reached all-time highs, up 26% and...
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023
DUBLIN , July 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2023 financial results and provide a business update after market close on Monday, Augus...
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy
DUBLIN , May 9, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that the US Food and Drug Administration (FDA) has granted Orph...
Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Q1 2023 YUPELRI® (revefenacin) net sales of $47.0 million, recognized by Viatris, up 8% from Q1 2022 1 Q1 2023 YUPELRI retail new patient starts and total prescriptions up 61% and 29%, respectively, y...
Theravance Biopharma to Report First Quarter 2023 Financial Results on May 8, 2023
DUBLIN , April 24, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2023 financial results and provide a business update after market close on Monday, May 8...
Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors
NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP (together with its affiliates, “Irenic” or “we”), a top shareholder of Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance” or the “Company”...
Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors
DUBLIN , April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Ass...
Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update
Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the program Discontinuing investments in research, reducing headcount by approx...
Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review
NEW YORK--(BUSINESS WIRE)--Irenic Capital Management, LP, a top shareholder of Theravance Biopharma, Inc. (NASDAQ: TBPH), today released the below letter. *** February 27, 2023 Theravance Biopharma, I...
Theravance Biopharma to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
DUBLIN , Feb. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2022 financial results and provide a business update after market close on...
Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets
Strategic priorities focused on continued Net Sales growth for YUPELRI® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS) in Multiple System Atrophy (MSA) patients with symptomati...
Theravance Biopharma, Inc. Announces Final Results of Tender Offer
DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the final results of its Dutch auction tender offer (the "Off...
Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer
DUBLIN , Nov. 18, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the preliminary results of its Dutch auction tender offer (th...
Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer
Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35% share) 1 Presented ampreloxetine data in neurog...
Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System
Totality of Evidence from the Phase 3 Clinical Program Demonstrates Ampreloxetine was Effective in Treating Symptoms and Improving Activities of Daily Living in MSA Patients with Neurogenic Orthostati...
Theravance Biopharma to Report Third Quarter 2022 Financial Results on November 7, 2022
DUBLIN , Oct. 31, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2022 financial results and provide a business update after market close on Monday, Novemb...
Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System
DUBLIN , Oct. 25, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension ...
Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
DUBLIN , Sept. 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced a "modified Dutch auction" tender offer (the "Offer") to pur...
Theravance Biopharma plans $250 million capital return program
Theravance Biopharma Inc. TBPH, +0.20% said Monday its board has authorized a $250 million capital return program, that includes buying back its own stock from GSK Plc GSK, -0.61% . The company will p...
Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program
The Company has agreed to purchase GSK's entire holdings at $9.75 per share The Company plans to launch a Dutch auction tender offer in the near term to purchase approximately $95 million of its ordin...
Theravance Biopharma to Present at Upcoming Investor Conferences
DUBLIN , Sept. 6, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) will be participating in the following Fireside Chats, both of which will be ...
Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Highest quarter of YUPELRI® (revefenacin) net sales and profitability to date 1 : $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) Ampreloxetine discussions with FDA create a path to NDA f...
Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022
DUBLIN , July 28, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2022 financial results and provide a business update after market close on Thursday, Aug...